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Abstract
SMN (Survival motor neuron protein) was characterized as a dimethyl-arginine binding protein over ten years ago. TDRD3
(Tudor domain-containing protein 3) and SPF30 (Splicing factor 30 kDa) were found to bind to various methyl-arginine
proteins including Sm proteins as well later on. Recently, TDRD3 was shown to be a transcriptional coactivator, and its
transcriptional activity is dependent on its ability to bind arginine-methylated histone marks. In this study, we systematically
characterized the binding specificity and affinity of the Tudor domains of these three proteins quantitatively. Our results
show that TDRD3 preferentially recognizes asymmetrical dimethylated arginine mark, and SMN is a very promiscuous
effector molecule, which recognizes different arginine containing sequence motifs and preferentially binds symmetrical
dimethylated arginine. SPF30 is the weakest methyl-arginine binder, which only binds the GAR motif sequences in our
library. In addition, we also reported high-resolution crystal structures of the Tudor domain of TDRD3 in complex with two
small molecules, which occupy the aromatic cage of TDRD3.
Citation: Liu K, Guo Y, Liu H, Bian C, Lam R, et al. (2012) Crystal Structure of TDRD3 and Methyl-Arginine Binding Characterization of TDRD3, SMN and SPF30. PLoS
ONE 7(2): e30375. doi:10.1371/journal.pone.0030375
Editor: Nick Gay, University of Cambridge, United Kingdom
Received July 21, 2011; Accepted December 15, 2011; Published February 17, 2012
Copyright:  2012 Liu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by the Structural Genomics Consortium, a registered charity (number 1097737) that receives funds from the Canadian
Institutes for Health Research, the Canadian Foundation for Innovation, Genome Canada through the Ontario Genomics Institute, GlaxoSmithKline, Karolinska
Institute, the Knut and Alice Wallenberg Foundation, the Ontario Innovation Trust, the Ontario Ministry for Research and Innovation, Merck & Co., Inc., the Novartis
Research Foundation, the Swedish Agency for Innovation Systems, the Swedish Foundation for Strategic Research and the Wellcome Trust. KL is supported by a
CCNU scholarship. MB is supported by National Institutes of Health grant number DK62248 and, in part, by institutional grant National Institute of Environmental
Health Sciences ES07784. R-MX acknowledges the support from the Natural Science Foundation of China (grants 90919029 & 3098801), the National Basic
Research Program of China (grants 2009CB825501 & 2010CB944903), and the Novo Nordisk-Chinese Academy of Sciences Foundation. The funders had no rolei n
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: rmxu@sun5.ibp.ac.cn (R-MX); jr.min@utoronto.ca (JM)
. These authors contributed equally to this work.
Introduction
Arginine methylation is an abundant covalent post-translational
modification, which regulates diverse cellular processes, including
transcriptional regulation, RNA processing, signal transduction and
DNA repair [1]. There are three types of arginine methylation, i.e.,
monomethylarginine (Rme1, or MMA), asymmetric dimethylargi-
nine (Rme2a, or aDMA) and symmetric dimethylarginine (Rme2s,
or sDMA). To date, nine protein arginine methyltransferases
(PRMT) have been identified in the human genome, and they can
be grouped into three classes. Type I PRMTs (PRMT1, 2, 3, 4, 6,
and 8) generate both monomethylarginine and asymmetric
dimethylarginine modifications. Type II PRMTs (PRMT5 and 7)
generate monomethylarginine and symmetric dimethylarginine
modifications. The only known type III PRMT generating only
monomethylarginine mark is PRMT7. Additionally, an atypical
type IV PRMT methylates the internal guanidine nitrogen atom,
which is only identified in yeast [1].
PRMTs can methylate a variety of target proteins, including
histones, Sm proteins and transcription factors [1,2,3]. Many of
these target proteins contain glycine and arginine-rich (GAR)
motifs, such as SmD1/3 and MIWI/PIWIL proteins [4,5]. Some
target proteins harbor PGM motifs [6]. Arginine residues within
the GAR and PGM motifs are the methyl-acceptor sites. Arginine
methylation can both positively and negatively regulate protein-
protein interactions of the target proteins. For examples, histone
H3R2 methylation by PRMT6 prevented methylation of H3K4
by the MLL family of histone H3K4 methyltransferase complexes
[7]. In addition, histone H3R2 methylation also blocks the binding
of H3K4me effectors, such as WDR5 [8,9] and BPTF [10] from
recognizing the H3K4me3 mark [7,11,12]. On the other hand,
arginine methylation can also create docking sites to foster protein-
protein interaction. So far, the Tudor domain is the only known
effector domain that is able to recognize methyl-arginine marks.
The Tudor domain is the founding member of the Tudor
domain ‘Royal Family’, which includes chromodomain, MBT
repeat domain and the PWWP domain [13]. Many members in
this family have been shown to bind lysine-methylated histones
and non-histone proteins [14,15]. Some Tudor domains have also
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domains are better known for binding methyl-arginine marks
[4,18,19,20,21]. In 2001, Friesen et al showed that the SMN
(survival of motor neurons) protein binds dimethylated GAR
motifs of SmD1 and SmD3 via its Tudor domain [4,22]. Another
study shows that SMN also binds methylated PGM motifs within
CA150, SAP49, SmB and U1C proteins, which are specifically
methylated by CARM1 [6]. SMN is a protein essential for
biogenesis of small nuclear ribonucleoproteins and its deficiency
causes spinal muscular atrophy disorders. In 2005, Cote and
Richard demonstrated that the Tudor domains of SMN and
SPF30 (Splicing factor 30 kDa, or SMNDC1, Survival motor
neuron domain-containing protein 1) and TDRD3 preferentially
recognize symmetrical dimethylated arginine motifs in proteins,
and arginine methylation and subsequent Tudor protein recruit-
ment is potentially important for the proper assembly and
localization of Sm proteins [18]. Through a protein domain
microarray, Yang et al recently discovered that TDRD3 also
functions as a arginine-methylated histone reader, which prefer-
entially recognizes H3R17me2a and H4R3me2a marks [21].
Interestingly, these histone sequences do not contain either GAR
or PGM motifs.
Although the Tudor domains of TDRD3, SMN and SPF30 have
been demonstrated to be methyl-arginine binders for a number of
years, their binding specificity and affinity has not been studied
systematically and quantitatively, and the molecular mechanism for
the recognition of methyl-arginine by their Tudor domains remains
elusive. The only structurally characterized interactions between a
Tudor domain and a methylated arginine involve recognition of
symmetrically dimethylated arginines of PIWI/MIWI proteins
[19,20]. In this report, we systematically characterized the binding
specificity and affinity of the Tudor domains of these three proteins
quantitatively, and report high resolution crystal structures of the
Tudor domain of TDRD3 with two small molecules, which
provides important insights into the structural basis of the methyl-
arginine recognition by the Tudor domain.
Results and Discussion
TDRD3 preferentially recognizes asymmetrical
dimethylated arginine mark
TDRD3 contains a Tudor domain at its C-terminus. The
Tudor domain of TDRD3 has been shown to recognize arginine-
methylated histones and Sm proteins [18,21]. In order to
characterize its binding specificity and affinity quantitatively, we
performed a series of fluorescence polarization (FP) binding assays
using our fluorescein-labeled peptide library, which includes GAR
motif-containing SmD3 and PIWIL1 peptides, PGM motif-
containing SmB peptides, and histone H3R2 peptides (Table 1
and Fig. 1). A low salt concentration (50 mM NaCl) is used in the
FP binding assay due to the weak binding affinities of these
proteins to their ligands. At this salt concentration, the binding
affinities are increased about four times compared to the data
measured at 200 mM NaCl (Fig. S1), which will save the reagents
and make the Kd measurement more reliable. Our data show that
TDRD3 (residues from 520 to 633) preferentially recognizes
asymmetrically dimethylated peptides over symmetrically di-
methylated peptides and monomethylated peptides, consistent
with two recent reports [21,23]. Therefore, TDRD3 has a
different binding selectivity than SND1, which we have previously
established that the extended Tudor domain of SND1 preferen-
tially binds symmetrically dimethylated arginine PIWIL1 peptides
[20]. Similar to SND1, the binding selectivity of TDRD3 among
these three different arginine methylation marks is about 2 to 4-
fold (Table 1) [20].
For SND1, we found that the canonical Tudor domain of
SND1 is not sufficient for binding its ligands. Its N-terminal and
C-terminal extensions, which fold together to form another
Tudor-like domain, are required for binding the methyl-arginine
PIWIL peptides [20]. Thus, we asked whether the Tudor domain
of TDRD3 is capable of binding its ligands by itself. To this end,
we used purified protein from our crystallization construct
(residues from 553 to 611), which only covers the canonical
Tudor domain, to test if the binding affinity is abolished, and
found that the crystallization construct has almost the same
binding affinity as the longer construct (residues from 520 to 633).
Hence, in regards to TDRD3, its Tudor domain is sufficient for
ligand binding.
Recently, it has been suggested that the Tudor domain of
TDRD3 preferentially recognizes H3R17me2a and H4R3me2a
peptides and promotes transcription by binding these methylargi-
nine marks [21,23]. Our ITC (Isothermal Titration Calorimetry)
binding results show that TDRD3 preferentially recognizes
H3R17me2a over H3R17me2s (Fig. 2), which is consistent with
our fluorescence polarization results for other methyl-arginine
peptides (Table 1). Very interestingly, the R17 residue does not
Figure 1. Fluorescence polarization binding curves of TDRD3 (aa 520–633), SMN (aa 80–170), and SPF30 (aa 65–150) to the PIWIL1-
R4 peptides. The buffer used in the fluorescence polarization assay is 20 mM Tris pH 7.5, 50 mM NaCl, 1 mM DTT and 0.01% Triton X-100. The data
are measured at 25uC and corrected for background by subtracting the free-labeled peptide background. The Kd values are the average of three
independent measurements.
doi:10.1371/journal.pone.0030375.g001
Methyl-Arginine Binding of TDRD3, SMN and SPF30
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e30375reside in a GAR motif, which is also the case in the methylated Pol
II CTD [23]. Therefore, the Tudor domain of TDRD3 does not
only bind GAR motif but also other motifs. In comparison, we also
measured the binding affinity of the PIWIL1_R4me2a peptide
with TDRD3 at the same conditions by ITC, which binds
modestly tighter than the H3R17me2a peptide (Fig. 2). On the
other hand, TDRD3 does not bind the methyl-arginine at the
PGM motifs (Table 1). Taken together, the Tudor domain of
TDRD3 preferentially binds asymmetrically dimethylated pep-
tides with a preference for GAR motifs.
Crystal structures of TDRD3 in complex with two methyl-
arginine mimics
In order to better understand the molecular mechanism of
methyl-arginine binding by the Tudor domain of TDRD3, we
tried cocrystallization of the TDRD3 Tudor domain with different
methyl-arginine peptides. Although we could not obtain cocrystals
of TDRD3 with any of these peptides, we found a tetraethylene
glycol (PG4) or isopropanol (2-propanol) molecule in our crystal
structures. These compounds are from our crystallization
solutions. Interestingly, these compounds bind to TDRD3 and
occupy the aromatic cage of TDRD3 (Fig. 3A and 3B).
The overall structure of the Tudor domain of TDRD3 is very
similar to that of the SMN Tudor domain with an RMSD of 1.1 A ˚
for all aligned Ca atoms (Fig. 3C). The TDRD3 and SMN Tudor
domains have a sequence identity of 37% (Fig. 4A). Consistent
with the SMN structure, the Tudor domain of TDRD3 exhibits a
five-stranded b-barrel fold (Fig. 3A). The tetraethylene glycol or
isopropanol molecule is bound in an aromatic rectangle cuboid
cage formed by the aromatic residues Y566, Y573, F591 and
Y594, reminiscent of the methylarginine binding by the SND1
Tudor domain [20] or Drosophila Tudor [19] (Fig. 3). The
tetraethylene glycol molecule exhibits a linear conformation,
parallel to the aromatic rings of residues Y566, Y573 and Y594
and perpendicular to residue F591 (Fig. 3A). Likewise, the
isopropanol molecule is flanked by the aromatic rings of residues
Y566 and Y594 with the hydrogen from the CH group pointing to
the aromatic ring of residue Y566 (Fig. 3B). Furthermore, by
superimposing the Tudor domain structures of TDRD3 with those
of the SND1-PIWIL1 peptide structures and the recently released
SMN/SPF30-methyl-arginine residue structures [24], we found
that the small molecules (PG4 or isopropanol) reside in a similar
position to the side chain of the methyl-arginine (Fig. 4B and 4C).
In the SND1 and PIWIL1 peptide complex structures, besides
the aromatic cage, the methyl-arginine also forms a hydrogen
bond with residue N768 through the NH1/2 group, and
disruption of this hydrogen bond severely diminishes the binding
[20]. Interestingly, in both the tetraethylene glycol and isopropa-
nol complex structures, the conserved asparagine N596 also forms
a hydrogen bond with the tetraethylene glycol or isopropanol
molecule, respectively. Thus, both the tetraethylene glycol and the
isopropanol molecule are bound by the aromatic cage and residue
N596 of TDRD3 through hydrophobic and hydrogen bonding
interactions. Nevertheless, during the submission of the manu-
script, NMR structures of SMN and SPF30 in complex with
methyl-arginine residues were released [24]. These newly released
structures show that SMN and SPF30 do not form hydrogen
bonds with their ligands (Fig. 4C). In the SMN and SPF30
structures, the methyl groups are attached to arginine in a different
configuration, which presents hydrogen bond formation between
the symmetrically dimethylated arginine and the conserved
asparagine (N132 in SMN and N113 in SPF30). In addition, the
dimethylated arginine pushes the asparagine away, which points to
solvent in the SMN and SPF30 structures (Fig. 4C).
Table 1. Binding affinities of TDRD3 (aa 520–633), SMN (aa 80–170), and SPF30 (aa 65–150) to different methyl-arginine peptides
in comparison with SND1 (aa 650–910).
Peptide Name Amino Acid Sequence Kd (mM)
TDRD3 (aa 520–633) SMN (aa 80–170) SPF30 (aa 65–150)
SND1 (aa 650–
910)
PIWIL1-R4un TGRARARARGRARGQE .500 .300 .500 9466*
PIWIL1-R4me1 TGRmeARARARGRARGQE .500 .150 .500 1961*
PIWIL1-R4me2a TGRme2aARARARGRARGQE .150 9763 .400 4262*
PIWIL1-R4me2s TGRme2sARARARGRARGQE .300 3462 .200 1061*
SmD3RSDMA GGRGRme2sGRG .400 9464N B 5 6 68
PGM(SmB165SD) YPPGRme2sGGPPP NB .300 NB .500
PGM(SmB214SD) PPGMRme2sPPPPG NB .400 NB NB
PGM(SmB221SD) PPGMRme2sGPPP NB .500 NB NB
H3R2me1 ARmeTKQTARKSY NB .300 NB .300
H3R2me2a ARme2aTKQTARKSY .500 .200 NB .300
H3R2me2s ARme2sTKQTARKSY .500 .150 NB 9966*
H3R17me2a TGGKAPRme2aKQLATKA .1000(ITC)
H3R17me2s TGGKAPRme2sKQLATKA NB(ITC)
H4R3me2a SGRme2aGKGGK NB(ITC)
Histone H3K4me1/2/3 ARTK (me)1/2/3 QTARKST NB NB NB NB*
Histone H3K9me1/2/3 ARTKQTARK(me)1/2/3STGGKA NB NB NB NB*
NB: No detectable binding.
*: data from Liu K et al, PNAS, 2010 [20].
doi:10.1371/journal.pone.0030375.t001
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PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e30375Figure 2. Preferential binding of TDRD3 to asymmetrical dimethylated H3R17 peptide over symmetrical dimethylated H3R17
peptide. The ITC measurements were done in 20 mM Tris pH 8.0 and 200 mM NaCl using the same TDRD3 construct as used in Table 1. The
measurements were taken at 25uC. Binding isotherms were plotted and analyzed using Origin Software (MicroCal Inc.). The ITC measurements were
fit to a one-site binding model. (A) Histone H3R17me2a peptide (TGGKAPRme2aKQLATKA). (B) Histone H3R17me2s peptide (TGGKAPRme2sKQ-
LATKA). (C) PIWIL1_R4me2a peptide (TGRme2aARARA).
doi:10.1371/journal.pone.0030375.g002
Figure 3. Crystal structures of TDRD3 with methyl-arginine mimics. (A) TDRD3 in complex with tetraethylene glycol (PG4). (B) TDRD3 in
complex with isopropanol. The aromatic cage residues and small molecules are displayed in a stick model. (C) Superposition of the crystal structures
of TDRD3 and SMN (PDB: 1MHN). The tetraethylene glycol molecule is shown in a stick model. SMN is colored in blue and TDRD3 is colored in green.
doi:10.1371/journal.pone.0030375.g003
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L3MBTL1/2 all have similar aromatic cages [17,19,20,25,26,27].
53BP1 and L3MBTL1 selectively bind low methylation states of
lysine in histone tails, but SND1 selectively recognized arginine
methylated peptides. By comparing the aromatic cage dimensions,
it was found that the distance between the F740 and Y766 in
SND1 is 1.2 A ˚ narrower than that between the Y1502 and Y1523
in 53BP1 [20]. The narrower cage size in the extended Tudor
domain of SND1 favors the planar methyl-guanidinium group. By
comparing the Tudor domain structure of TDRD3 and SND1, it
was found that the aromatic cage has a very similar size to that of
SND1 (Fig. 4B), which explains why TDRD3 selectively binds
methyl-arginine proteins, but not methyl-lysine proteins (Table 1).
SMN preferentially recognizes symmetrically
dimethylated peptides
SMN protein is a core component of the SMN complex, which
plays an essential role in spliceosomal snRNP assembly in the
cytoplasm and is required for pre-mRNA splicing in the nucleus
[28]. Recessive mutations in the SMN1 gene cause all four types of
spinal muscular atrophy disorders (SMA1–4). Dreyfuss’s labora-
tory showed that SMN preferentially binds to the dimethylated
GAR motifs of SmD1 and SmD3, and methylation also promotes
its interaction with other SMN-interacting proteins [4]. Peptide
competition assay by Brahms et al implicated that SMN
preferentially binds symmetrically dimethylated Sm proteins D1/
D3, B/B9 and the Sm-like protein LSm [29]. Symmetrical
dimethylation of the Sm proteins is carried out by PRMT5 and
PRMT7 [30,31]. Whitehead et al argued that arginine dimethyla-
tion is not required for SMN recognition of proteins bearing GAR
motifs, although they agreed that GAR motif is essential in SMN
binding [32]. In another study, it was also shown that the Tudor
domain of SMN interacts with the EWS protein (Ewing’s sarcoma
protein) via its GAR motifs, but symmetrical dimethylation
reduces this interaction [33]. In addition to the GAR motifs,
SMN is also able to bind the PGM motifs of CA150, SmB, and
other splicing factors in a CARM1-dependent fashion. CARM1
carries out arginine monomethylation and asymmetric dimethyla-
tion [6]. In order to reconcile the differences among these reports,
we systematically characterized the binding property of SMN
using our fluorescein-labeled peptide library by means of
fluorescence polarization binding assays.
Our binding results show that SMN preferentially recognizes
symmetrically dimethylated arginine peptides (Table 1). It binds
the symmetrical dimethylated peptide of the PIWIL1 protein
(PIWIL1_R4me2s) with a Kd of 34 mM. The binding affinity was
about 3 times weaker for the asymmetrical dimethylated PIWIL1
peptide (PIWIL1_R4me2a, Kd=97 mM), over 4 times weaker for
the monomethylated PIWIL1 peptide (PIWIL1_R4me1,
Kd.150 mM). Interestingly, SMN also binds the unmethylated
PIWIL1 peptide (Table 1), consistent with some reports suggesting
that arginine methylation is not crucial for binding GAR motif
containing proteins [32,33]. A similar trend holds for the different
modifications of histone H3R2 peptides, which does not have a
GAR motif. In agreement with the fact that SMN binds PGM
motif containing proteins in a methylation-dependent manner,
Figure 4. Structural comparison of TDRD3 to SND1 and SPF30. (A) Structure-based sequence alignment of the Tudor domain of TDRD3,
SPF30 and SMN. The aromatic cage residues are denoted by black dots. Identical residues are colored in white on red background, and similar
residues are colored in red. (B) Superposition of the crystal structures of TDRD3 and SND1 (PDB: 3OMC). SND1 is colored in cyan and its bound ligand
PIWIL1_R4me2s peptide is shown in a stick model. (C) Superposition of the crystal structures of TDRD3 and SPF30 (PDB: 4A4F). The tetraethylene
glycol molecule and methyl-arginine are shown in a stick model. SPF30 is colored in blue and TDRD3 is colored in green.
doi:10.1371/journal.pone.0030375.g004
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protein SmB, albeit with lower affinity in comparison to the GAR
motif containing SmD1/3 and PIWIL1 peptides. Like TDRD3,
the Tudor domain of SMN is sufficient for binding. The SMN
construct covering only the Tudor domain (residues 82–147) binds
to the PIWIL1_R4me2s peptide with a Kd of 46 mM. Taken
together, SMN is a very promiscuous effector molecule, which
preferentially binds symmetrical dimethylated arginine via its
Tudor domain.
In this study, we report the high-resolution crystal structures of
the Tudor domain of TDRD3, and the high-resolution structure of
SMN has been reported previously [22,34]. By comparing the
ligand binding grooves of these two proteins (Fig. 5), we found that
SMNdisplays a much wider bindinggroovenear the aromatic cage,
which could potentially explain why SMN is a very promiscuous
effector molecule binding different motifs, especially PGM motifs.
Proline acts as a secondary structural element disruptor, and is often
found in turns. In order to accommodate the proline-rich PGM
motifs, it is conceivable that a larger binding groove, such as that
identified in the SMN Tudor domain, is essential. That explains
why SMN is a very promiscuous effector molecule.
SPF30, a homolog of SMN, also contains a Tudor domain,
which has a 45% sequence identity with the SMN Tudor domain
(Fig. 4A). Our binding results show that SPF30 only binds the
GAR motif containing PIWIL1 peptides with a lower affinity in
comparison to TDRD3 and SMN (Table 1). Therefore, although
TDRD3, SMN and SPF30 all contain a conserved Tudor domain,
they exhibit different binding properties.
In summary, in this study, we systematically characterized the
binding specificity and affinity of the Tudor domains of TDRD3,
SMN, and SPF30 quantitatively, which show that TDRD3
preferentially recognizes asymmetrical dimethylated arginine
mark, and SMN is a very promiscuous effector molecule, which
recognize different arginine containing sequence motifs and
preferentially binds symmetrical dimethylated arginine. SPF30 is
the weakest methyl-arginine binder, which only binds the GAR
motif sequences. These Tudor domains have been reported to
exhibit weak binding affinity (mM scale) to SmD3 methyl-arginine
peptides by NMR titration [22], which is significantly lower
compared to other methyl-lysine/arginine Tudor binders, such as
JMJD2A [16], 53BP1 [17], SGF29 [35] and SND1 [20], but
comparable to FXR1/2 [36] and PWWP proteins [37] By peptide
screening, we identified some higher affinity ligands for the
TDRD3 and SMN Tudors, which means that ligands of stronger
binding affinities with these Tudor domains potentially exist,
which warrants further investigation in the future. In addition, we
report high resolution crystal structures of the Tudor domain of
TDRD3 with two methyl-arginine mimics, which provides the first
glimpse of methyl-arginine binding by these Tudor domains.
Materials and Methods
Protein preparation and crystallization
Different length of TDRD3, SMN and SPF30 fragments
covering the Tudor domain were amplified from human cDNA
and sub-cloned into pET28-MHL vector. The recombinant
proteins were overexpressed at 14uC in Escherichia coli BL21
(DE3) overnight as N-terminal His-tagged fusion proteins. Freezed
Cell pellets were re-suspended in 200 ml lysis buffer (16PBS,
pH 7.2–7.4, 250 mM NaCl, 5% glycerol) for every 40 g cell pellet.
Adding 20 unit Benzoate Nuclease, 0.2 mM PMSF, 0.2% CHAPS,
20 mM b-mercaptoethanol and were purified by affinity chroma-
tography on Ni-NTA. TDRD3 protein used for crystallization was
cleaved using TEV by incubating at 4uC for overnight. All of the
eluted proteins were collected and purified further by size exclusion
chromatography (HiLoad 16/60 Superdex 75, GE) in a buffer of
20 mM Tris pH 7.0, 200 mM, 1 mM DTT, respectively. Protein
was concentrated to 10 mg/ml and crystallized by sitting-drop
vapor diffusion. The PG4 cocrystal was grown at 0.1 M Tris-HCl
pH 8.5, 2.0 M Ammonium sulfate and PEG400 additive at 18uC.
The isopropanol crystal was grown in a condition with 10% 2-
propanol, 100 mM Phosphate-Citrate pH 4.0 and 0.2 M Li2SO4.
Peptide binding Assays
All the regular and fluorescent peptides used this study were
synthesized by Tufts University Core Services (Boston, USA). The
fluorescence polarization assay was carried out as described before
[38]. The buffer used in the fluorescence polarization assay is
20 mM Tris pH 7.5, 50 mM NaCl, 1 mM DTT and 0.01% Triton
X-100. An excitation wavelength of 485 nm and an emission
Figure 5. Surface representation of TDRD3 and SMN. (A) TDRD3 (B) SMN (PDB: 1MHN). The ligand is superimposed from the TDRD3-PG4 structure.
doi:10.1371/journal.pone.0030375.g005
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and corrected for background by subtracting the free-labeled
peptide background. The data were collected by the Synergy 2
(BioTec, USA) fluorescence polarization program and were fit to
one-site binding model using Origin 7 (MicroCal, Inc.). The Kd
values are the average of three independent measurements.
The protocol for ITC (Isothermal Titration Calorimetry) was
carried out as described before [39]. The ITC buffer used in this
study is 20 mM Tris pH 8.0 and 200 mM NaCl. The measure-
ments were taken at 25uC. Binding isotherms were plotted and
analyzed using Origin Software (MicroCal Inc.). The ITC
measurements were fit to a one-site binding model.
Data collection, structure determination and refinement
Diffraction data for the TDRD3-PG4 crystal were collected at
100 uK using CuKa radiation generated on a Rigaku FR-E
SuperBright rotating anode system equipped with VariMax HF
optics and a Saturn A200 CCD detector. Data were integrated
and scaled using the HKL2000 software package [40]. The
structure of the Tudor domain of human Tudor domain-
containing protein 3 was solved using the single-wavelength
anomalous dispersion (SAD) method [41] utilizing the anomalous
signal from one sulfur atom corresponding to a highly ordered Cys
residue present in the crystal. The position of the sulfur anomalous
scatterer was determined using SHELXD [42], followed by heavy-
atom refinement and maximum-likelihood-based phasing as
implemented in the autoSHARP program suite [43]. Phase
improvement by density modification generated an interpretable
experimental electron density map, which allowed an initial model
of the polypeptide chain to be traced using ARP/wARP [44].
Following several alternate cycles of manual rebuilding using
COOT [45] and restrained refinement against a maximum
likelihood target, the improved model revealed clear electron
densities allowing placement of water molecules. All refinement
steps were performed using REFMAC [46] in the CCP4 proegram
suite suite. During the final cycles of model building, TLS
parameterization [47] was included in the refinement of the final
model which comprised protein and solvent molecules. The
diffraction data for the TDRD3-isopropanol crystal was collected
on a Rigaku 007 generator and a R-AXIS detector. The structure
was determined by molecular replacement using Molrep [48] and
refined in a similar protocol to the TDRD3-PG4 structure. The
data collection and refinement statistics are summarized in
Table 2.
Supporting Information
Figure S1 Binding affinities of TDRD3 to PIWIL1
peptides at 200 mM NaCl. The buffer used in the fluorescence
polarization assay is 20 mM Tris pH 7.5, 200 mM NaCl, 1 mM
DTT and 0.01% Triton X-100. The data are measured at 25uC
and corrected for background by subtracting the free-labeled
peptide background. The Kd values are the average of three
independent measurements.
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